Drug General Information (ID: DDIOR6NWYQ)
Drug Name			Vincristine		Drug Info		Guselkumab		Drug Info
Drug Type		Small molecule				Monoclonal antibody
Therapeutic Class		Antineoplastics				Interleukin Inhibitors

Mechanism of Vincristine-Guselkumab Interaction (Severity Level: Moderate)
Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Vincristine				Guselkumab
Mechanism 1		Immunosuppressive effects				Immunosuppressive effects
Key Mechanism Factor 1
		Factor Name		Immunosuppressive effects
		Factor Description		Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
Mechanism Description		Additive immunosuppressive effects by the combination of Vincristine and Guselkumab
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Vincristine				Guselkumab
Mechanism 2		Myelosuppressive effects				Myelosuppressive effects
Key Mechanism Factor 2
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Vincristine and Guselkumab

Recommended Action
Management		Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.

References
1	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2	Product Information. Actemra (tocilizumab). Genentech, South San Francisco, CA.
3	Product Information. Amevive (alefacept). Biogen, Cambridge, MA.
4	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
5	Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.
6	Product Information. Ilaris (canakinumab). Novartis Pharmaceuticals, East Hanover, NJ.
7	Product Information. Stelara (ustekinumab). Centocor Inc, Malvern, PA.
8	Product Information. Sylvant (siltuximab). Janssen Biotech, Inc., Horsham, PA, PA.
9	Product Information. Taltz Autoinjector (ixekizumab). Eli Lilly and Company, Indianapolis, IN.